Switching from tenofovir DF to TAF improves bone and kidney safety
Modest kidney function decline in people taking Truvada for PrEP supports need for monitoring
TAF/emtricitabine maintains viral suppression as well as TDF regimens with less bone and kidney toxicity
Direct-acting antivirals reduce cryoglobulinemia in hepatitis C
Survival and outcome analysis shows that selected HIV-positive patients are good candidates for liver and kidney transplant
Two-drug maintenance therapy keeps viral load suppressed and may even have advantages over traditional ART
Benefits of early HIV treatment are clear, but issues raised by START and D:A:D remain unresolved
